Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database

被引:6
作者
Li, Xiaoduo [1 ]
Yang, Qiao [2 ]
Chen, Mingjing [3 ]
Yang, Changqing [4 ]
Gu, Jianfen [5 ]
Dong, Qiang [6 ]
Yang, Guangrong [4 ]
机构
[1] Qijiang Maternal & Child Hlth Hosp, Dept Obstet & Gynecol, Chongqing, Peoples R China
[2] PLA Joint Logist Support Force, Dept Ultrasound, Hosp 941, Xining, Qinghai, Peoples R China
[3] Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China
[4] Chongqing Med Univ, Dept Oncol, Qijiang Hosp, Affiliated Hosp 1, Chongqing 401420, Peoples R China
[5] Chongqing Med Univ, Dept Nutr, Qijiang Hosp, Affiliated Hosp 1, Chongqing, Peoples R China
[6] Chongqing Med Univ, Dept Gen Med, Qijiang Hosp, Affiliated Hosp 1, Chongqing 401420, Peoples R China
关键词
Primary peritoneal serous carcinoma; Advanced serous ovarian carcinoma; Clinical features; Overall survival; SEER; PAPILLARY CARCINOMA; CANCER; METASTASIS; PROGNOSIS; WOMEN;
D O I
10.1186/s13048-021-00788-y
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective This study aimed to compare clinical features and overall survival (OS) between patients with primary peritoneal serous carcinoma (PPSC) and those with advanced serous ovarian carcinoma (ASOC) and to identify prognostic factors. Methods Patients diagnosed with PPSC and ASOC from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were enrolled. Pearson's chi-square test was used to compare clinical features. The primary endpoint was OS. The Kaplan-Meier method and log-rank test were used to perform the survival analysis. Propensity score matching was also conducted. Univariate, multivariate and subgroup analyses were performed using the Cox proportional hazards model. Results A total of 708 PPSC patients and 7610 ASOC patients were enrolled. The clinical features of PPSC patients were noticeably different from those of ASOC patients. The survival analysis showed that PPSC patients had poorer outcomes than ASOC patients. Even after the clinical features were balanced, PPSC patients still had poorer survival. Univariate and multivariate analyses indicated that older age, higher tumor grade and advanced American Joint Committee on Cancer stage were adverse prognostic factors in both groups, while surgery and chemotherapy were protective factors. A subgroup analysis demonstrated that most factors favored ASOC patients. The total distant metastasis rates of PPSC and ASOC were similar. Liver or lung metastasis was common, but bone and brain metastases were rare. A higher proportion of liver metastasis was observed in the ASOC group. Conclusion The clinical features and survival outcomes between PPSC patients and ASOC patients are clearly different, and PPSC is more aggressive than ASOC.
引用
收藏
页数:10
相关论文
共 32 条
  • [1] NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
    Armstrong, Deborah K.
    Alvarez, Ronald D.
    Bakkum-Gamez, Jamie N.
    Barroilhet, Lisa
    Behbakht, Kian
    Berchuck, Andrew
    Berek, Jonathan S.
    Chen, Lee-may
    Cristea, Mihaela
    DeRosa, Marie
    ElNaggar, Adam C.
    Gershenson, David M.
    Gray, Heidi J.
    Hakam, Ardeshir
    Jain, Angela
    Leath, Charles A., III
    Liu, Joyce
    Mahdi, Haider
    Matei, Daniela
    McHale, Michael
    McLean, Karen
    O'Malley, David M.
    Penson, Richard T.
    Percac-Lima, Sanja
    Ratner, Elena
    Remmenga, Steven W.
    Sabbatini, Paul
    Werner, Theresa L.
    Zsiros, Emese
    Burns, Jennifer L.
    Engh, Anita M.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (08): : 896 - +
  • [2] Primary peritoneal serous papillary carcinoma: A study of 25 and comparison with stage Ill-IV ovarian papillary serous carcinoma
    BenBaruch, G
    Sivan, E
    Moran, O
    Rizel, S
    Menczer, J
    Seidman, DS
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 60 (03) : 393 - 396
  • [3] Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma - a Gynecologic Oncology Group Study
    Bloss, JD
    Brady, MF
    Liao, SY
    Rocereto, T
    Partridge, EE
    Clarke-Pearson, DL
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 89 (01) : 148 - 154
  • [4] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [5] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
  • [6] Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan
    Chao, Kuan-Chong
    Chen, Yi-Jen
    Juang, Chi-Mou
    Lau, Hei-Yu
    Wen, Kuo-Chang
    Sung, Pi-Lin
    Fang, Feng-Ying
    Twu, Nae-Fang
    Yen, Ming-Shyen
    [J]. TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2013, 52 (01): : 81 - 84
  • [7] Chu C S, 1999, Obstet Gynecol Surv, V54, P323, DOI 10.1097/00006254-199905000-00023
  • [8] Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients
    Deng, Kui
    Yang, Chunyan
    Tan, Qilong
    Song, Wei
    Lu, Mingliang
    Zhao, Weiwei
    Lou, Ge
    Li, Zhenzi
    Li, Kang
    Hou, Yan
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 460 - 465
  • [9] The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications
    Duska, L. R.
    Kohn, E. C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 8 - 12
  • [10] Prognostic factors in extraovarian primary peritoneal carcinoma
    Eltabbakh, GH
    Werness, BA
    Piver, S
    Blumenson, LE
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 71 (02) : 230 - 239